Aminocaproic Acid
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Aminocaproic Acid
- Aminocaproic Acid: From Antifibrinolytic Therapy to Severe Nonproliferative Diabetic Retinopathy
Aminocaproic Acid: From Antifibrinolytic Therapy to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Aminocaproic acid is generally known as an antifibrinolytic (a lysine analog that inhibits plasminogen activation). The provided data does not list an approved indication. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but there are currently 0 clinical trials and 0 publications supporting this direction, so it rests on a model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the provided data (all license records have empty indication text) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.27% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the records shown are ANDA generic approvals) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the input. Based on general knowledge, aminocaproic acid is an antifibrinolytic that blocks plasminogen activation. Any mechanistic link to diabetic retinopathy is therefore unverified and would need confirmation from primary sources.
The only support is the TxGNN knowledge-graph score of 0.993. A plausible but unproven connection is to bleeding-related complications of proliferative disease, such as vitreous hemorrhage. That is a different problem from severe nonproliferative disease itself, which is the predicted indication. The relationship between the original and predicted indications is therefore not established.
Safety is also a concern. Antifibrinolytics carry thrombotic risk, and diabetic patients already have elevated vascular risk. A high model score alone is not evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The first five of the 20 authorizations are listed below. The provided data has no approved-indication text for any of them.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA212492 | Aminocaproic acid | Tablet | Major Pharmaceuticals |
| ANDA213928 | Aminocaproic acid | Tablet | Carnegie Pharmaceuticals, LLC |
| ANDA212938 | Aminocaproic acid | Tablet | Novadoz Pharmaceuticals LLC |
| ANDA071192 | Aminocaproic acid | Injection, solution | Medical Purchasing Solutions, LLC |
| ANDA213928 | Aminocaproic acid | Tablet | Biocon Pharma Inc. |
Available routes in the market data: oral (tablet) and injectable (injection, solution).
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction records were available in the provided data.
As a general class concern (not from label data), antifibrinolytics carry thrombotic risk, which matters for patients with diabetes.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a knowledge-graph score, with no trials, literature, or mechanistic data behind it. Package insert safety data is also missing. The plausible link (vitreous hemorrhage) does not match the predicted indication (severe nonproliferative disease). The thrombotic risk in a high-vascular-risk population adds further caution.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data, for example from DrugBank
- A systematic literature and trial search on antifibrinolytics in diabetic retinopathy and vitreous hemorrhage
- Confirmation of the approved original indication
- Route compatibility assessment, since systemic oral or injectable use is available but the target tissue is the retina
- A thrombotic risk assessment in diabetic patients
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.